Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Trial in Progress: Phase 2 Study of Subcutaneous Isatuximab, Administered By an on-Body Delivery System, in Combination with Weekly Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (SubQSA)

Tondre T. Buck, Clark Cutrer, Nashat Y. Gabrail, George F. Geils, Jr., Alexander Philipovskiy, Hayman S. Salib, Yvonne Barnes, Pamela Brill, Taro Fukao, Florence Leroy-Carita, Jesús G Berdeja

Blood (2024) 144 (Supplement 1): 4757.2.

https://doi.org/10.1182/blood-2024-203880

Published: 2024

Journal Articles

Fatalities from Tumor Lysis Syndrome (TLS) after Anti-Hyperuricemic Monotherapy - Nationally Representative, Propensity Score Matched, Retrospective Study Comparison of Rasburicase and Allopurinol

Mitchell S Cairo, Jack R Gallagher, Yvonne Barnes, Edward Drea, Susan Carroll

Blood (2022) 140 (Supplement 1): 8136.

https://doi.org/10.1182/blood-2022-169864

Published: 2022

Journal Articles

Clinical Practice Utilization and Outcomes with Rasburicase Vs Allopurinol for Patients at High Risk of Tumor Lysis Syndrome

Janna Radtchenko, Daniel Lyons, Yvonne Barnes, Scott Milligan, Edward Drea, PharmD

Blood (2019) 134 (Supplement_1): 2203.

https://doi.org/10.1182/blood-2019-124319

Published: 2019

Journal Articles

The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children’s Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial

Michael A. Pulsipher, Bryan Langholz, Donna A. Wall, Kirk R. Schultz, Nancy Bunin, William L. Carroll, Elizabeth Raetz, Sharon Gardner, Julie M. Gastier-Foster, Denise Howrie, Rakesh K. Goyal, James G. Douglas, Michael Borowitz, Yvonne Barnes, David T. Teachey, Candace Taylor, Stephan A. Grupp

Blood (2014) 123 (13): 2017–2025.

https://doi.org/10.1182/blood-2013-10-534297

Published: 2014

Journal Articles

Pharmacokinetics of Alemtuzumab Used as Conditioning Agent in Reduced Intensity Transplantation for Pediatric Non-Malignant Disorders.

Julie Kanter, MD, Manasa Kanthamneni, Shannon Witty, Yvonne Barnes, Robert Hayashi, Shalini Shenoy

Blood (2008) 112 (11): 3290.

https://doi.org/10.1182/blood.V112.11.3290.3290

Published: 2008

Journal Articles

Reduced Intensity Conditioning Therapy Using Campath -1H Is Successful for Stem Cell Transplantation in Non-Malignant Disorders.

Aarati Rao, MD, Robert Hayashi, MD, William Grossman, MD, PhD, David Wilson, MD, PhD, Lolie Yu, MD, John DiPersio, MD, PhD, Yvonne Barnes, PNP, Shalini Shenoy, MD

Blood (2004) 104 (11): 1823.

https://doi.org/10.1182/blood.V104.11.1823.1823

Published: 2004

NARROW

Trial in Progress: Phase 2 Study of Subcutaneous Isatuximab, Administered By an on-Body Delivery System, in Combination with Weekly Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (SubQSA)

Fatalities from Tumor Lysis Syndrome (TLS) after Anti-Hyperuricemic Monotherapy - Nationally Representative, Propensity Score Matched, Retrospective Study Comparison of Rasburicase and Allopurinol

Clinical Practice Utilization and Outcomes with Rasburicase Vs Allopurinol for Patients at High Risk of Tumor Lysis Syndrome

The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children’s Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial

Pharmacokinetics of Alemtuzumab Used as Conditioning Agent in Reduced Intensity Transplantation for Pediatric Non-Malignant Disorders.

Reduced Intensity Conditioning Therapy Using Campath -1H Is Successful for Stem Cell Transplantation in Non-Malignant Disorders.

Email alerts

ASH Publications

American Society of Hematology

Trial in Progress: Phase 2 Study of Subcutaneous Isatuximab, Administered By an on-Body Delivery System, in Combination with Weekly Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (SubQSA)

Fatalities from Tumor Lysis Syndrome (TLS) after Anti-Hyperuricemic Monotherapy - Nationally Representative, Propensity Score Matched, Retrospective Study Comparison of Rasburicase and Allopurinol

Clinical Practice Utilization and Outcomes with Rasburicase Vs Allopurinol for Patients at High Risk of Tumor Lysis Syndrome

The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children’s Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial

Pharmacokinetics of Alemtuzumab Used as Conditioning Agent in Reduced Intensity Transplantation for Pediatric Non-Malignant Disorders.

Reduced Intensity Conditioning Therapy Using Campath -1H Is Successful for Stem Cell Transplantation in Non-Malignant Disorders.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only